Koers Inspyr Therapeutics, Inc. Other OTC
Aandelen
NSPX
US45782A4031
Biotechnologie & Medisch Onderzoek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 241K 222K |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | 2 mln. 1,84 mln. | Nettowinst (verlies) 2022 | -1 mln. -922K | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 197K 182K | Nettoschuld 2022 | 305K 281K | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-0,4
x | K/w-verhouding 2022 |
-0,23
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 11-10-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Scott Ogilvie
BRD | Director/Board Member | 69 | 01-02-08 |
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Claire Thomas
BRD | Director/Board Member | 68 | 12-10-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,83% | 118 mld. | |
+10,80% | 106 mld. | |
-10,84% | 23,4 mld. | |
-1,69% | 22,1 mld. | |
-10,23% | 18,34 mld. | |
-41,92% | 16,59 mld. | |
-15,11% | 15,97 mld. | |
+6,62% | 14,03 mld. | |
+17,53% | 11,67 mld. |